Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DAWN Day One Biopharmaceuticals	$6.40 -0.1%	$6.59	$6.08 ▼ $16.76	$651.14M	-1.27	1.16 million shs	404,220 shs
IBRX ImmunityBio	$2.67 -3.1%	$2.79	$1.83 ▼ $7.48	$2.37B	0.08	6.36 million shs	3.01 million shs
MIRM Mirum Pharmaceuticals	$51.89 -0.1%	$48.30	$36.20 ▼ $54.78	$2.57B	0.97	447,780 shs	85,163 shs
OGN Organon & Co.	$9.46 +0.0%	$9.52	$8.01 ▼ $23.10	$2.46B	0.6	3.62 million shs	1.07 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DAWN Day One Biopharmaceuticals	0.00%	-5.74%	+1.27%	-10.36%	-57.28%
IBRX ImmunityBio	0.00%	-2.14%	-4.18%	+9.56%	-52.50%
MIRM Mirum Pharmaceuticals	0.00%	-1.39%	+3.16%	+35.27%	+31.50%
OGN Organon & Co.	0.00%	-4.83%	-3.12%	-11.34%	-54.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DAWN Day One Biopharmaceuticals	2.9171 of 5 stars	3.6	3.0	0.0	0.0	3.1	2.5	0.0
IBRX ImmunityBio	1.8489 of 5 stars	3.6	1.0	0.0	0.0	1.1	1.7	0.6
MIRM Mirum Pharmaceuticals	3.5063 of 5 stars	2.6	0.0	0.0	4.2	3.4	2.5	0.6
OGN Organon & Co.	4.8524 of 5 stars	3.3	3.0	1.7	3.7	2.4	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DAWN Day One Biopharmaceuticals	3.14	Buy	$29.00	353.48% Upside
IBRX ImmunityBio	3.20	Buy	$12.25	359.66% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	26.22% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	90.19% Upside

Current Analyst Ratings Breakdown

Latest DAWN, OGN, IBRX, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DAWN Day One Biopharmaceuticals	$131.16M	4.94	N/A	N/A	$4.99 per share	1.28
IBRX ImmunityBio	$14.74M	159.58	N/A	N/A	($0.57) per share	-4.68
MIRM Mirum Pharmaceuticals	$336.89M	7.63	N/A	N/A	$4.70 per share	11.04
OGN Organon & Co.	$6.40B	0.38	$4.93 per share	1.92	$1.83 per share	5.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.71	N/A	N/A	N/A	-42.66%	-14.98%	-13.04%	7/29/2025 (Estimated)
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.28	2.53	0.98	11.92%	227.43%	7.34%	8/5/2025 (Estimated)

Latest DAWN, OGN, IBRX, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	IBRX ImmunityBio	-$0.10	N/A	N/A	N/A	$21.95 million	N/A
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	N/A	N/A	N/A	$107.91 million	N/A
8/5/2025	Q2 2025	OGN Organon & Co.	$0.93	N/A	N/A	N/A	$1.55 billion	N/A
7/29/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	N/A	N/A	N/A	$35.55 million	N/A
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.85%	N/A	2.78%	N/A

Latest DAWN, OGN, IBRX, and MIRM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DAWN Day One Biopharmaceuticals	N/A	10.62	10.55
IBRX ImmunityBio	N/A	2.22	2.05
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
OGN Organon & Co.	16.49	1.67	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DAWN Day One Biopharmaceuticals	87.95%
IBRX ImmunityBio	8.58%
MIRM Mirum Pharmaceuticals	N/A
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
DAWN Day One Biopharmaceuticals	6.20%
IBRX ImmunityBio	76.79%
MIRM Mirum Pharmaceuticals	22.87%
OGN Organon & Co.	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	95.08 million	Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	38.21 million	Optionable
OGN Organon & Co.	4,000	259.96 million	256.32 million	Not Optionable

DAWN, OGN, IBRX, and MIRM Headlines

Recent News About These Companies

DEADLINE TOMORROW: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class Action by July 22, 2025

2 hours ago | globenewswire.com

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

4 hours ago | prnewswire.com

The Gross Law Firm Notifies Shareholders of Organon & Co.(OGN) of a Class Action Lawsuit and an Upcoming Deadline

4 hours ago | prnewswire.com

ORGANON & CO. (NYSE: OGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Organon & Co. Investors of Upcoming Deadline

5 hours ago | globenewswire.com

INVESTOR DEADLINE TOMORROW: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OGN

July 21 at 5:40 AM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

July 20 at 10:55 AM | globenewswire.com

Optimist Retirement Group LLC Raises Stock Holdings in Organon & Co. (NYSE:OGN)

July 20 at 8:59 AM | marketbeat.com

OGN SECURITIES NEWS: Did Organon & Co. ...

July 20 at 8:26 AM | gurufocus.com

OGN SECURITIES NEWS: Did Organon & Co. (NYSE:OGN) Commit Securities Fraud? Contact BFA Law by July 22 Class Action Deadline

July 20 at 7:05 AM | globenewswire.com

Foundry Partners LLC Lowers Holdings in Organon & Co. (NYSE:OGN)

July 20 at 6:18 AM | marketbeat.com

OGN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. ...

July 19 at 5:22 PM | gurufocus.com

OGN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important July 22 Deadline in Securities Class Action – OGN

July 19 at 4:45 PM | globenewswire.com

ORGANON DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. ...

July 19 at 11:31 AM | gurufocus.com

ORGANON DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit

July 19 at 10:50 AM | globenewswire.com

TUESDAY INVESTOR DEADLINE: Organon & Co. ...

July 18 at 11:32 PM | gurufocus.com

TUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 18 at 10:00 PM | prnewswire.com

Organon (OGN) Registers a Bigger Fall Than the Market: Important Facts to Note

July 18 at 6:51 PM | zacks.com

ORGANON 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Organon & Co. - OGN

July 18 at 6:00 PM | businesswire.com

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July ...

July 18 at 5:01 PM | gurufocus.com

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July 22, 2025 Deadline to file Lead Plaintiff Motion

July 18 at 4:46 PM | globenewswire.com

Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy ...

July 18 at 12:08 PM | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Investors Are Waking Up to Arista Networks—Here’s the Scoop
By Jeffrey Neal Johnson | June 26, 2025
View Investors Are Waking Up to Arista Networks—Here’s the Scoop

DAWN, OGN, IBRX, and MIRM Company Descriptions

Day One Biopharmaceuticals NASDAQ:DAWN

$6.40 -0.01 (-0.08%)

As of 12:30 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

ImmunityBio NASDAQ:IBRX

$2.66 -0.09 (-3.09%)

As of 12:30 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$51.89 -0.04 (-0.07%)

As of 12:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Organon & Co. NYSE:OGN

$9.46 +0.00 (+0.04%)

As of 12:30 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time